24/7 Market News Snapshot 25 June, 2025 – Precision BioSciences, Inc. Common Stock (NASDAQ:DTIL)

June 25, 2025

DENVER, Colo., 25 June, 2025 (www.247marketnews.com) – (Nasdaq:DTIL) are discussed in this article.
Precision BioSciences, Inc. (Nasdaq:DTIL) is witnessing a significant surge in its stock value, currently trading at $5.529, reflecting an impressive increase of 20.98% from the previous close of $4.570. This notable movement is accompanied by a trading volume of approximately 1.64 million shares, signaling robust investor interest and confidence. Such performance could be indicative of positive market sentiment regarding the company’s future prospects, particularly in light of its recent achievements in gene editing technology.

In a pivotal development, Precision BioSciences has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its promising therapeutic candidate, PBGENE-DMD, aimed at treating Duchenne muscular dystrophy (DMD). This designation recognizes the urgent medical needs of children suffering from this debilitating condition and underscores the potential impact of the therapeutic option being developed.

Cindy Atwell, the Chief Development and Business Officer, highlighted the significance of this designation, emphasizing the pressing need for innovative treatments for DMD. The PBGENE-DMD candidate utilizes the company’s proprietary ARCUS® gene editing platform to target and excise specific segments of the dystrophin gene, aiming to restore functional dystrophin protein production in approximately 60% of patients affected by DMD.

Initial preclinical studies have shown encouraging results, indicating substantial and lasting improvements in muscle function in a humanized DMD mouse model. The prospective treatment aims to offer a permanent solution by enabling enduring production of dystrophin, a protein crucial for muscle integrity.

Moreover, securing the Rare Pediatric Disease Designation could enable Precision BioSciences to obtain a Priority Review Voucher upon FDA approval, facilitating an expedited review process for future product candidates. As the company advances through its final IND-enabling studies, initial clinical data for PBGENE-DMD is anticipated in 2026, marking a crucial step toward addressing the needs of children impacted by DMD. Precision BioSciences remains dedicated to utilizing its innovative ARCUS platform to drive transformative solutions for various genetic disorders, reinforcing its commitment to improving patient outcomes through cutting-edge therapies.

Related news for (DTIL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.